Literature DB >> 10487692

Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes.

V Lazar1, J M Bidart, B Caillou, C Mahé, L Lacroix, S Filetti, M Schlumberger.   

Abstract

The expression of 4 thyroid tissue-specific genes [Na+/I- symporter (NIS), thyroid peroxidase (TPO), thyroglobulin (Tg), TSH receptor (TSH-R)] as well as of the glucose transporter type 1 (Glut1) gene was analyzed in 90 human thyroid tissues Messenger ribonucleic acids were extracted from 43 thyroid carcinomas (38 papillary and 5 follicular), 24 cold adenomas, 5 Graves' thyroid tissues, 8 toxic adenomas, and 5 hyperplastic thyroid tissues; 5 normal thyroid tissues were used as reference. A kinetic quantitative PCR method, based on the fluorescent TaqMan methodology and real-time measurement of fluorescence, was used. NIS expression was decreased in 40 of 43 thyroid carcinomas (10- to 1200-fold) and in 20 of 24 cold adenomas (2- to 700-fold); it was increased in toxic adenomas and Graves' thyroid tissues (up to 140-fold). TPO expression was decreased in thyroid carcinomas, but was normal in cold adenomas; it was increased in toxic adenomas and Graves' thyroid tissues Tg expression was decreased in thyroid carcinomas, but was normal in the other tissues. TSH-R expression was normal in most tissues studied and was decreased in only some thyroid carcinomas. In thyroid cancer tissues, a positive relationship was found between the individual levels of expression of NIS, TPO, Tg and TSH-R. No relationship was found with the age of the patient. Higher tumor stages (stages >I vs stage I) were associated with lower expression of NIS (P = 0.03) and TPO (P < 0.01). Expression of the Glut1 gene was increased in 1 of 24 adenomas and in 8 of 43 thyroid carcinomas. In 6 thyroid carcinoma patients, 131I uptake was studied in vivo; NIS expression was low in all samples; 3 patients with normal Glut-1 gene expression had 131I uptake in metastases, whereas the other 3 patients with increased Glut-1 gene expression had no detectable 131I uptake. In conclusion, this study shows 1) a reduced expression of NIS gene in most hypofunctioning benign and malignant thyroid tumors; 2) a differential regulation of the expression of thyroid-specific genes; 3) an increased expression of Glut-1 gene in some malignant tumors that may suggest a role for glucose derivative tracers to detect in vivo thyroid cancer metastases by positron emission tomography scanning.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10487692     DOI: 10.1210/jcem.84.9.5996

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  70 in total

1.  Embryonic epithelial Pten deletion through Nkx2.1-cre leads to thyroid tumorigenesis in a strain-dependent manner.

Authors:  Saverio Bellusci; Parviz Minoo; Caterina Tiozzo; Soula Danopoulos; Maria Lavarreda-Pearce; Sheryl Baptista; Radka Varimezova; Denise Al Alam; David Warburton; Rehan Virender; Stijn De Langhe; Antonio Di Cristofano
Journal:  Endocr Relat Cancer       Date:  2012-04-10       Impact factor: 5.678

2.  Indium-111 octreotide scintigraphy for the detection of non-functioning metastases from differentiated thyroid cancer: diagnostic and prognostic value.

Authors:  Marcel P M Stokkel; Robbert B Verkooijen; Jan W A Smit
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-26       Impact factor: 9.236

3.  On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer.

Authors:  Paolo Zanotti-Fregonara; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12       Impact factor: 9.236

4.  Methylation of sodium iodide symporter promoter correlated with aggressiveness and metastasis in papillary thyroid carcinoma: a meta-analysis.

Authors:  Jun-Yu Zhao; Huan-Jun Wang; Hai-Peng Wang; Jin-Ming Yao; Xiao-Yun Wu; Hong-Xia Shang; Rui Zhang; Huan-Gao Zhu; Jian-Jun Dong; Lin Liao
Journal:  Int J Clin Exp Med       Date:  2015-07-15

5.  Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations.

Authors:  Ludovic Lacroix; Vladimir Lazar; Stefan Michiels; Hugues Ripoche; Philippe Dessen; Monique Talbot; Bernard Caillou; Jean-Pierre Levillain; Martin Schlumberger; Jean-Michel Bidart
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

6.  What role for recombinant human TSH in the treatment of metastatic thyroid cancer?

Authors:  Paolo Zanotti-Fregonara; Elif Hindié; Marie Elisabeth Toubert; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06       Impact factor: 9.236

Review 7.  Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond.

Authors:  Prasanna Santhanam; Lilja B Solnes; Steven P Rowe
Journal:  Med Oncol       Date:  2017-10-30       Impact factor: 3.064

8.  A Nonpump Function of Sodium Iodide Symporter in Thyroid Cancer via Cross-talk with PTEN Signaling.

Authors:  Fang Feng; Lamis Yehia; Ying Ni; Yi Seok Chang; Sissy Meihua Jhiang; Charis Eng
Journal:  Cancer Res       Date:  2018-09-14       Impact factor: 12.701

9.  (99m)Tc-labeled-rhTSH analogue (TR1401) for imaging poorly differentiated metastatic thyroid cancer.

Authors:  Filippo Galli; Isabella Manni; Giulia Piaggio; Lajos Balogh; Bruce D Weintraub; Mariusz W Szkudlinski; Valerie Fremont; Rudi A J O Dierckx; Alberto Signore
Journal:  Thyroid       Date:  2014-06-20       Impact factor: 6.568

10.  Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways.

Authors:  Peng Hou; Ermal Bojdani; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2009-12-11       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.